Your Next Generation
Radiopharmaceutical
Platform
of Radiopharmaceuticals
The Promise and Potential
-
Clinically validated improvement in overall survival
-
Strong large pharmaceutical interest
'Bristol Myers to buy
RazeBio for $4.1 BILLION
in targeted cancer therapy push.'
-By Bhanvi Satija
HOWEVER
-
Current radiopharmaceuticals utilizing beta-emitters have limitations
-
Beta-emitters like Pluvicto have low potency and long range
Alpha-Emitter approaches utilizing Actinium-225
also have many significant limitations
Alpha-emitters like Actinium have stronger potency but suffer from:
-
Difficult decay scheme (three free alpha decays per one on target decay)
-
Difficult raw material sourcing (e.g. sourcing with nuclear stockpiles)
-
Lack of direct imaging makes clinical development difficult
-
Logistical nightmare re: potential instability and contamination
The leader in utilizing the next generation Alpha-Emitter Astatine
-
Ideal nuclear decay scheme for clinical efficacy and safety with one alpha-particle per Astatine-211 decay
-
Abundant polonium x-rays for direct clinical imaging
-
Short 7.2 hour half-life ideal for patient/hospital/production safety
-
Properties similar to iodine so ideal for conjugation for large AND small molecules
MEET OUR TEAM
A company that is led by a seasoned management team with deep expertise
in oncology and radiopharmacuticals
Michael Zalutsky, PhD
CSO
Professor Radiology,
Duke University
Martin Pomper, MD, PhD
Senior Director of Translation
Chair Radiology, University Texas
at South Western
Tracy Shearer, BSN
Head of Development Operations
Heartwood, Intellia, Astellas
Philippe Pultar, MD
Head of Clinical Development
Zentalis, Novartis, Imclone
BLUE CHIP INVESTORS
